Current cancer treatments often fail to address the full spectrum of tumor-specific antigens, leading to limited efficacy and potential for relapse in patients with solid tumors and immune-mediated diseases. Existing cell therapies may not be tailored to the unique T-cell clones present in individual disease tissues.

T-Cypher Bio develops T-cell receptor (TCR)-based therapeutics by identifying functionally-defined T-cell clones directly from patient disease tissues using proprietary target screening libraries. This approach enables the creation of personalized cell therapies that target a broader range of tumor-specific antigens, addressing the limitations of existing cancer treatments. The company's high-throughput, high-resolution profiling of the immune synapse allows for mapping of the intracellular target space and profiling of T-cell specificity. T-Cypher Bio's platforms generate large immune system datasets that support computational modeling of T-cell repertoires, providing insights into T-cell immunology and facilitating the development of innovative drugs.

Proprietary target screening libraries for identifying functionally-defined T-cell clones.

High-throughput, high-resolution profiling of the immune synapse.

Identification of novel, shared, tumor-specific targets.

Validation of rare, functionally-defined T-cell clones.

Computational modeling of T-cell repertoires for enhanced target discovery.

TCR-based therapeutics for solid tumors and immune-mediated diseases.

The primary target audience includes healthcare providers specializing in oncology and immunology, as well as patients with solid tumors and immune-mediated diseases who could benefit from tailored cell therapies.